Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

28.06 -0.49 (-1.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roivant Sciences Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Analyst Expectations for Roivant Sciences's Future ↗
 
Via Benzinga
News headline image
Why Shares of Roivant Sciences Rose Wednesday ↗
The pharmaceutical company released fourth-quarter earnings. 
Via The Motley Fool
News headline image
UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Nasdaq, S&P 500 Futures Slip Ahead Of Powell Speech, Bank Stress Test Results: Why This Analyst Rates Stocks 'Overweight' And Says 'Buy Weakness' ↗
 
Via Benzinga
News headline image
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Roivant Sciences Stock is Trading Higher Today ↗
Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with  
Via Benzinga
News headline image
A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout ↗
The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. 
Via Investor's Business Daily
News headline image
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
News headline image
5 Analysts Have This to Say About Roivant Sciences ↗
 
Via Benzinga
News headline image
Why Shares of Roivant Sciences Jumped This Week ↗
The company's stock benefited from another company's buyout. 
Via The Motley Fool
News headline image
Why Roivant Sciences Stock Is Perking Up Today ↗
Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. 
Via The Motley Fool
News headline image
Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period
From Roivant Sciences
Via GlobeNewswire
News headline image
Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
From Roivant Sciences
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 ↗
 
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission ↗
Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... 
Via Benzinga
News headline image
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
From Roivant Sciences
Via GlobeNewswire
News headline image
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? ↗
Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. 
Via The Motley Fool
News headline image
These 2 Growth Stocks Might Be Incredibly Undervalued Right Now ↗
These two biopharma stocks could be poised for a major growth spurt. 
Via The Motley Fool
News headline image
EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis ↗
While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. 
Via Benzinga
News headline image
These 3 Nasdaq Stocks Are on Fire Today: Here's Why ↗
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
News headline image
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom ↗
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... 
Via Benzinga
News headline image
Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory
From Lokavant
Via Business Wire
News headline image
Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research
From Lokavant
Via Business Wire
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients
From Covant Therapeutics
Via GlobeNewswire
News headline image
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.